Bispecific Antibody Therapeutics Market Analysis and Size
In a single molecule, bispecific antibodies have two antigen-binding sites. Bispecific antibodies appear in a variety of sizes and shapes, ranging from tiny proteins with two associated antigen-binding fragments to massive IgG-like molecules with additional domains. The therapeutic success of currently existing bispecific antibodies has accelerated bispecific antibody development in oncology.
According to Globaldata's database, 106 bispecific antibody compounds are in development. 45 of the 106 bispecific antibody medicines in clinical development are aimed mostly at blood cancers, while the rest are aimed at solid tumors, mostly lung and gastrointestinal cancers.
In 2018, approximately 4,285,033 new cancer cases were detected in China, according to Globocan's estimations. As a result, the increased global prevalence of cancer necessitates new therapeutic choices, driving up demand for bispecific antibodies. Bispecific antibodies (BsAbs) are antibodies that can bind two distinct antigens simultaneously (or different epitopes of the same antigen). BsAbs have mostly been used to reroute cytotoxic immune effector cells for improved tumor cell killing via antibody-dependent cell-mediated cytotoxicity (ADCC) and other cytotoxic processes mediated by effector cells.
Get PDF Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bispecific-antibody-therapeutics-market
Bispecific Antibody Therapeutics Market Dynamics
Drivers
· High prevalence rate of cancer
The rise in prevalence rate of cancer across the globe will act as a major driver that will result in the expansion of the market's growth rate. According to the World Health Organization (WHO), cancer, after cardiovascular disorders, is the world's second greatest cause of death, according to the World Health Organization (WHO). It is, nonetheless, one of the most preventable chronic non-communicable diseases. Reduced tobacco use, healthier diets and physical exercise, reduced alcohol usage, and other measures can save approximately 40% of all cancer deaths. Sedentary lifestyle adoption is on the rise, indicating that a huge number of people are active, putting them at a higher risk of contracting cancer. Furthermore, a sedentary lifestyle that includes the consumption of fast food and packaged materials increases the risk of cancer. As a result, an increase in sedentary lifestyle adoption reflects an increase in cancer incidences, necessitating the development of improved cancer therapies.
· Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of the bispecific antibody therapeutics market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, a surging number of government initiatives to spread awareness and increasing the geriatric population will result in the expansion of the bispecific antibody therapeutics market. Along with this, changing lifestyle of people and growing government favorable initiatives will enhance the growth rate of the market.
Opportunities
· Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the bispecific antibody therapeutics market growth.
· Rising number of strategic collaborations
Key players in the global bispecific antibodies market are also looking to buy companies that provide specialized products and projects with the potential to produce significant income. Manufacturers in the market attempt to have a stronger product portfolio than their competitors by acquiring these companies. Amgen Inc. announced the acquisition of Five Prime Therapeutics in March 2021. Amgen's premier cancer portfolio now includes Five Prime's breakthrough pipeline. These factors will boost new market opportunities during the forecast period of 2022-2029.
Get TOC Details of Report@ https://www.databridgemarketresearch.com/toc/?dbmr=global-bispecific-antibody-therapeutics-market
Global Bispecific Antibody Therapeutics Market Scope
The bispecific antibody therapeutics market is segmented on the basis of indication, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
· Oncology
· Autoimmune Disease
· Others
Drugs
· Blinatumomab
· Catumaxomab
· Duligotumab
· Others
Route of Administration
· Intravenous
· Subcutaneous
· Others
End-Users
· Hospitals
· Specialty Clinics
· Homecare
· Others
Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online Pharmacy
· Others
Some of the major players operating in the bispecific antibody therapeutics market are:
· Pfizer Inc. (U.S.)
· GlaxoSmithKline plc (U.K.)
· Novartis AG (Switzerland)
· Sanofi (France)
· AstraZeneca (U.K.)
· F. Hoffmann-La Roche Ltd. (Switzerland)
· Eli Lilly and Company (U.S.)
· Allergan (Ireland)
· Innovent Biologics, Inc. (China)
· Adimab (U.S.)
· Affimed GmbH (Germany)
· Xencor (U.S.)
· Pieris Pharmaceuticals, Inc. (U.S.)
· Mereo BioPharma Group plc (U.K.)
· Sobi (Sweden)
· TG Therapeutics, Inc (U.S.)
· Merus (Netherlands)
· MacroGenics, Inc (U.S.)
· Genmab A/S (Denmark)
· Emergent BioSolutions Inc (U.S.)
· Alteogen (South Korea)
· Astellas Pharma Inc. (Japan)
Browse in-depth Research Report @ https://www.databridgemarketresearch.com/reports/global-bispecific-antibody-therapeutics-market
About us: -
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in pune.
Data bridge market research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and ha bridge market research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact us: -
Data bridge market research
Us: +1 888 387 2818
Email: - corporatesales@databridgemarketresearch.com
